Actively Recruiting

Phase 1
Age: 18Years - 55Years
All Genders
Healthy Volunteers
ID06724640

A Phase 1 Double-Blind, Placebo-Controlled, Randomized Study to Assess Safety, Tolerability, and Pharmacokinetics of VH4011499 in Adults Without HIV

Led by ViiV Healthcare · Updated on 2025-10-29

168

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the safety, tolerability, and how the body processes VH4011499 when given in single or multiple doses to adults without HIV. This Phase 1 trial aims to understand how the drug behaves in healthy adults aged 18 to 55 and to monitor any side effects or reactions over time. Participants will be randomly assigned to receive either a low or high dose of VH4011499 or a placebo. The drug is given by injection, either under the skin or into the muscle. Some participants will receive a single dose while others will get multiple doses. The study includes an initial dosing period and long-term follow-up extending up to 78 weeks. During the study, participants will undergo regular assessments including blood tests to measure drug levels and liver function, as well as monitoring for any side effects such as injection site reactions. Researchers will track safety over time and collect data on how the drug is absorbed and eliminated. Participation involves visits over many months to evaluate these outcomes carefully.

CONDITIONS

Brief Title

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

Who Can Participate

Age: 18Years - 55Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Be between 18 and 55 years old at the time of consent
  • Be overtly healthy
  • Be male or female
  • Female participants must not be pregnant, not breastfeeding, and either be of nonchildbearing potential or use highly effective contraception during the study
  • Be capable of giving signed informed consent
Not Eligible

You will not qualify if you...

  • History or presence of significant cardiovascular, respiratory, liver, kidney, endocrine, blood, nervous system, or psychiatric disorders
  • Abnormal blood pressure
  • History of lymphoma, leukemia, or other cancers within the past 5 years except certain skin cancers
  • Breast cancer within the past 10 years
  • Current or chronic liver disease or abnormalities
  • Clinically relevant hepatitis within the last 6 months
  • Chronic hepatitis B infection
  • History of allergies to study interventions
  • Skin conditions interfering with injection site assessment
  • Insufficient muscle for safe intramuscular injection
  • High-risk behaviors increasing HIV risk
  • Conditions interfering with study compliance or safety
  • Use of medications within 7 days prior to dosing
  • Exposure to more than 4 investigational products in the past 12 months
  • Current or recent participation in another investigational study
  • Positive HIV antibody/antigen test
  • Elevated liver enzymes or bilirubin beyond set limits
  • Reduced kidney function below specified threshold
  • Regular use of tobacco, nicotine, alcohol, or drugs of abuse
  • Prolonged QT interval or heart rhythm abnormalities
  • Tattoos, silicone implants, or fillers at injection sites that may interfere with assessments

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 78 weeks

Participants receive either a single dose or two doses of VH4011499 or placebo via injection to assess safety, tolerability, and pharmacokinetics.

Multiple visits for dosing and assessments up to Week 78

Trial Site Locations

Total: 2 locations

1

GSK Investigational Site

Las Vegas, Nevada, United States, 89113

Actively Recruiting

2

GSK Investigational Site

Austin, Texas, United States, 78744

Actively Recruiting

Loading map...

Research Team

U

US GSK Clinical Trials Call Center

E

EU GSK Clinical Trials Call Center

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

ACTION HIV: A Global Record of Patients With Anal Squamous C...

Anal Squamous Cell Carcinoma

Actively Recruiting

1 location

A Long-term Follow-up Study for HIV-infected Individuals Who...

HIV Infections

Actively Recruiting

1 location

A Phase 2b Randomized, Open-Label Study Evaluating Oral VH45...

HIV Infections

Actively Recruiting

113 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here